Prospective Evaluation of the Quality of Life of Patients With Post-thrombotic Syndrome Who Receive Compression Therapy and Sulodexide - SQUARES Study
This study aims to evaluate whether, in a standardised cohort of patients with mild to moderate PTS, monitored for a sufficiently long follow-up period, quality of life measured by generic instruments and disease-specific instruments evolves favourably in this patient profile.
Study objective: to evaluate the evolution of quality of life in general and in the specific context of the disease of patients who have experienced an episode of deep-vein thrombosis (DVT), are affected by post-thrombotic syndrome, are subject to compression therapy and receive an additional standard venoactive agent (sulodexide 15 mg twice daily during 6 months).
100 Clinical Results associated with Bama-Geve, S.L.U.
0 Patents (Medical) associated with Bama-Geve, S.L.U.
100 Deals associated with Bama-Geve, S.L.U.
100 Translational Medicine associated with Bama-Geve, S.L.U.